Ascendis Pharma (ASND) Misses Q3 EPS by 48c
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Join SI Premium – FREE
Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR2.88), EUR0.48 worse than the analyst estimate of (EUR2.40). Revenue for the quarter came in at EUR48.03 million versus the consensus estimate of EUR48.91 million.
For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- AutoZone beats profit view but misses on revenue
- Aytu BioScience (AYTU) Tops Q4 EPS by 28c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
